Key Highlights

  • 163.55 million in USD is the gross cash consideration from Sangamo Therapeutics, Inc. (OTCQB:SGMO) asset sales, including USD 111 million from PTC Therapeutics and USD 50 million from Eli Lilly, with milestones of up to USD 100 million.
  • 31.0 million in USD was the net loss for the first quarter of 2026, or USD 0.08 per share, compared with a net loss of USD 30.6 million, or USD 0.14 per share, a year earlier.
  • 1.4 million in USD was first quarter 2026 revenue, down from USD 6.4 million a year earlier, mainly because of a 2025 Pfizer sublicense transfer, while cash and equivalents stood at USD 27.6 million at March 31, 2026.
  • 26.6 million in USD was first quarter Research and Development expense, against USD 26.0 million a year earlier, while general and administrative expense fell to USD 6.8 million from USD 10.1 million.

What Investors Expect From Sangamo Therapeutics, Inc. (OTCQB:SGMO) on November 16, 2026

Sangamo Therapeutics is scheduled to report on November 16, 2026. The company is now operating under Chapter 11, filed on June 23, 2026 in the U.S. Bankruptcy Court for the District of Delaware under Case No. 26-10989, and its shares now quote under the symbol SGMOQ on an over-the-counter market. The most recent full quarterly figures in the company release cover the first quarter of 2026, when Revenue was USD 1.4 million and the net loss was USD 31.0 million on 389.6 million weighted shares.

The Rationale: Last Reported Quarter and Management Outlook for Sangamo Therapeutics, Inc. (OTCQB:SGMO)

In the first quarter report of May 2026, GAAP operating expenses were USD 33.4 million versus USD 36.1 million, and non-GAAP operating expenses were USD 31.7 million versus USD 32.5 million. Management then guided 2026 GAAP operating expenses of about USD 110 million to USD 130 million and non-GAAP operating expenses of about USD 100 million to USD 120 million, subject to additional funding, and said cash would fund operations into the third quarter of 2026. CEO Sandy Macrae said the company remained focused on regulatory and clinical priorities. The company announced a strategic alternatives review on June 8, 2026.

Valuation, Liquidity and Risks for Sangamo Therapeutics, Inc. (OTCQB:SGMO)

At March 31, 2026, total Assets were USD 60.0 million and the stockholders' Deficit was USD 19.0 million. Nasdaq suspended trading on May 5, 2026 after a minimum bid price deficiency, the shares moved to the OTCQB Venture Market, and the Nasdaq Hearings Panel denied the appeal on July 14, 2026. The asset sale proceeds repaid the debtor-in-possession financing, a process for the ST-503 chronic neuropathic pain program was set for the fourth quarter of 2026, and the PTC milestones are USD 80 million on Accelerated Approval and USD 20 million on full approval.

Where Things Stand

Sangamo Therapeutics, Inc. (OTCQB:SGMO) reports on November 16, 2026 as a company that has largely sold its pipeline through Chapter 11. Total sale proceeds were USD 163.55 million, which included USD 2.55 million for tools and equipment, and the first quarter net loss of USD 31.0 million is now a historical benchmark rather than a guide to future operations. Attention is likely to center on residual assets, the ST-503 auction, the PTC milestones of up to USD 100 million and what the Chapter 11 process means for Equity holders. This article is informational and is not Investment advice.